Abcuro, a clinical-stage biotechnology company focused on developing immunotherapies for autoimmune diseases and cancer, has announced the successful completion of a $200 million Series C financing. The funding round was led by New Enterprise Associates with participation from Foresite Capital and existing investors, including RA Capital Management, Bain Capital Life Sciences, and others. The proceeds will support the ongoing Phase 2/3 MUSCLE clinical trial for ulviprubart (ABC008), a monoclonal antibody targeting killer cell lectin-like receptor G1 (KLRG1) for the treatment of inclusion body myositis (IBM). If trial results are positive, Abcuro plans to file a Biologics License Application and prepare for commercial launch.
Ulviprubart is designed to selectively deplete highly cytotoxic T cells while preserving other immune cells. IBM is a progressive autoimmune disease-causing muscle weakness and atrophy, affecting more than 50,000 individuals across the U.S. and Europe. There are currently no disease-modifying treatments available for IBM. Abcuro expects to report initial trial data in the first half of 2026 and will also use the funds to expand manufacturing capabilities. The company continues to advance its clinical development efforts, with ulviprubart also being investigated for T-cell large granular lymphocytic leukemia.
